# Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer

Source: https://onco.cc/trials/nct06443671/  
OnCo record `nct06443671` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of cAPOX (capecitabine, oxaliplatin), fruquintinib and tislelizumab in colorectal cancer, run by Peking University Cancer Hospital & Institute, not yet recruiting.

## Summary

Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer is a phase 2/3, randomised interventional study registered as NCT06443671 by Peking University Cancer Hospital & Institute, with a registry enrolment figure of 132 participants, started 2024-06-01 and due to reach its primary completion in 2026-06-01. Interventions recorded: CapeOX; Fruquintinib and Tislelizumab combined with mCapeOX. Conditions listed: Rectal Cancer. Primary outcome: Pathological complete response(pCR) rates. Colorectal eligibility wording from the registry: "* Histologically confirmed rectal adenocarcinoma; Immunohistochemistry suggests pMMR, or PCR suggests MSS type patients;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: PKUCH-R09
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06443671
- Phase: 2/3
- Setting: Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Open-label, Multicenter, Randomized Controlled Trial
- Sponsor: Peking University Cancer Hospital & Institute
- Enrolled: 132

## Sources

- ClinicalTrials.gov NCT06443671: https://clinicaltrials.gov/study/NCT06443671

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06443671.json